{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:25:50Z","timestamp":1781969150468,"version":"3.54.5"},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Hepato Biliary Pancreat"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To describe the real\u2010world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary infection in Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients diagnosed with BTC and prescribed systemic therapy between January 2011 and September 2020 were retrieved from the Japanese Medical Data Vision database. The look\u2010back period was set to 5\u2009years. Patient characteristics, treatment patterns, and biliary infection\u2010induced treatment interruption were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The full analysis set comprised 22\u2009742 patients with a mean age of 71.0\u2009years and 61.6% were male. The most common BTC type was extrahepatic cholangiocarcinoma (44.6%). The three most common first\u2010line regimens were S\u20101 monotherapy (33.0%), gemcitabine+cisplatin (32.5%), and gemcitabine monotherapy (18.7%) over the entire observation period (January 2011\u2013September 2021). Patients who received monotherapies tended to be older. Biliary infection\u2010induced treatment interruption occurred in 29.5% of patients, with a median time to onset of 64.0 (interquartile range 29.0\u2013145.0) days. The median duration of intravenous antibiotics was 12.0 (interquartile range 4.0\u201392.0) days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results demonstrated potential challenges of BTC in Japanese clinical practice particularly use of multiple regimens, commonly monotherapies, which are not recommended as first\u2010line treatment, and the management of biliary infections during systemic therapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jhbp.1418","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T06:39:08Z","timestamp":1600756748000},"page":"468-480","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real\u2010world evidence of systemic treatment practices for biliary tract cancer in Japan: Results of a database study"],"prefix":"10.1002","volume":"31","author":[{"given":"Makoto","family":"Ueno","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division Kanagawa Cancer Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Shirakawa","sequence":"additional","affiliation":[{"name":"Oncology Medical AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Tokumaru","sequence":"additional","affiliation":[{"name":"Oncology Medical AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizue","family":"Ogi","sequence":"additional","affiliation":[{"name":"Evidence and Observational Research, Medical AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Nishida","sequence":"additional","affiliation":[{"name":"Evidence and Observational Research, Medical AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Hirai","sequence":"additional","affiliation":[{"name":"Evidence and Observational Research, Medical AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Shinozaki","sequence":"additional","affiliation":[{"name":"Oncology Medical AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Hamada","sequence":"additional","affiliation":[{"name":"Oncology Medical AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Oncology Medical AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Horiguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery Fujita Health University School of Medicine  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"National Cancer Center.Cancer registry and statistics: gallbladder and bile duct.2022. Accessed September 7 2023. Available from:https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/9_gallbladder.html"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy082"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.870"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"e_1_2_10_8_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Guidelines in Oncology: Biliary Tract Cancers version 3.2023.2023.Accessed December 1 2023. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/btc.pdf"},{"key":"e_1_2_10_9_1","first-page":"725","article-title":"Chemotherapy for biliary tract cancer: real\u2010world experience in a single institute","volume":"82","author":"Maeda O","year":"2020","journal-title":"Nagoya J Med Sci"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000500832"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5794"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-022-00331-5"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-021-00266-3"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-022-00296-5"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000758"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.1219"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz402"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31144"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100614"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0673-7"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0095-3"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.709234"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02038-4"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i26.6065"},{"key":"e_1_2_10_25_1","unstructured":"Japanese Society of Hepato\u2010Biliary\u2010Pancreatic Surgery.Tokyo Guidelines 2018. Accessed March 30 2023. 2018. Available from:http:\/\/www.jshbps.jp\/modules\/en\/index.php?content_id=47"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-021-04289-0"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.02.027"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.823705"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.002"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i19.3027"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101750"}],"container-title":["Journal of Hepato-Biliary-Pancreatic Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jhbp.1418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jhbp.1418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T12:23:28Z","timestamp":1722255808000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jhbp.1418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/jhbp.1418"],"URL":"https:\/\/doi.org\/10.1002\/jhbp.1418","archive":["Portico"],"relation":{},"ISSN":["1868-6974","1868-6982"],"issn-type":[{"value":"1868-6974","type":"print"},{"value":"1868-6982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"2023-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}